✦ LIBER ✦

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2vasopressin receptor antagonist in normal subjects

✍ Scribed by M. Burnier; A. F. Fricker; D. Hayoz; J. Nussberger; H. R. Brunner

Book ID: 105923059
Publisher: Springer
Year: 1999
Tongue: English
Weight: 110 KB
Volume: 55
Category: Article
ISSN: 0031-6970
DOI: 10.1007/s002280050685

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacological characterization of YM08

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

✍ A. Tahara; M. Saito; T. Sugimoto; Y. Tomura; K. Wada; T. Kusayama; J. Tsukada; N 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 83 KB

Vascular Effects of RWJ-676070, a Select

Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist

✍ Coltamai, L; Bucher, M; Maillard, MP; Shukla, U; Bohidar, N; Haskell, L; Bertels 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 322 KB

ChemInform Abstract: Recent Advances in

ChemInform Abstract: Recent Advances in the Discovery and Development of Vasopressin Antagonists: Peptide and Nonpeptide V1a and V2 Receptor Antagonists

✍ J. D. ALBRIGHT; P. S. CHAN 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 2 views

Effects of YM471, a nonpeptide AVP V1A a

Effects of YM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells

✍ Junko Tsukada; Atsuo Tahara; Yuichi Tomura; Koh-ichi Wada; Toshiyuki Kusayama; N 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 234 KB

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses

Molecular analysis of antilipemic effect

Molecular analysis of antilipemic effects of FR218944, a novel vasopressin V1a receptor antagonist, in genetically diabetic db/db mice in comparison with pioglitazone and fenofibrate

✍ Masahiko Morita; Akiko Ohkubo-Suzuki; Tokiko Takahashi; Akira Nagashima; Yuki Sa 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB